20.18 0.00 (0.00%)
After hours: 4:10PM EST
|Bid||20.16 x 900|
|Ask||20.17 x 1300|
|Day's Range||19.99 - 20.89|
|52 Week Range||11.31 - 33.13|
|Beta (3Y Monthly)||2.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 20, 2020 - Feb. 24, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||42.56|
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Insmed (INSM) delivered earnings and revenue surprises of -3.03% and 12.20%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners...
Insmed (INSM) delivered earnings and revenue surprises of 4.71% and 20.56%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
In 2012 Will Lewis was appointed CEO of Insmed Incorporated (NASDAQ:INSM). This report will, first, examine the CEO...
Insmed (INSM) delivered earnings and revenue surprises of 0.00% and 0.01%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
How far off is Insmed Incorporated (NASDAQ:INSM) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the foreast future cash flows of the company and dis...
PALM BEACH, Florida, April 10, 2019 /CNW/ -- According to the Centers for Disease Control, autism affects an estimated 1 in 59 children in the United States today. The Autism Speaks website defines the main problem for researchers/practitioners as: "We know that there is not one autism but many subtypes, most influenced by a combination of genetic and environmental factors. Because autism is a spectrum disorder, each person with autism has a distinct set of strengths and challenges. Medicines for treating the three core symptoms of autism – communication difficulties, social challenges and repetitive behavior – have long represented a huge area of unmet need.
PALM BEACH, Florida, April 9, 2019 /CNW/ -- In the last few years the number of clinical trials looking for new treatments for Leukemia (AML) has continued to grow. In 2017, a report from ManagedCare said that: "… There are over 400 phase 2 or phase 3 trials currently recruiting or underway for the treatment of AML…" As of April 8, 2019 that number had grown to 1,448 according to ClinicalTrials.gov, an arm of the National Institutes of Health: U.S. National Library of Medicine. The ManagedCare article said: "Acute myeloid leukemia (AML), sometimes called acute granulocytic leukemia, is the most common of the four major types of leukemia… This is a cancer that is rarely seen before age 45 with the average age of onset around 65… Treatment for AML can vary based on a number of factors, but in general the first-line therapy consists of induction therapy.
Insmed (INSM) delivered earnings and revenue surprises of -5.41% and 96.19%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Small-cap and large-cap companies receive a lotRead More...
NEW YORK, Feb. 07, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.